A study shows pollution causes a 22–25% rise in heart attacks, asthma, and bronchitis, according to Dr. GC Khilnani, Chairman of PSRI Institute of Pulmonary, Critical Care & Sleep Medicine.

What comes to mind when you think about asthma? For Dr. Laurent Couetil, horses are top of mind. His focus is to learn more ...

The FDA approved tezepelumab-ekko (TEZSPIRE; AstraZeneca/Amgen) on Friday as an add-on maintenance treatment in patients aged ...

Chiesi USA's asthma inhaler could simplify treatment for millions of Americans. Triangle Forward: What's Next for Life Sciences?

There are steps physicians can take to prepare their patients with pulmonary issues for the changing of the seasons.

The new tool, available as a phone app, helps identify comorbidities and produces a score to guide clinicians.

C HICAGO -- Adverse event risks varied across biologics used by asthma patients, an analysis of data submitted to the FDA ...

Linda Klonsky usually orders her prescription eye drops from a Canadian pharmacy that charges $250 for a three-month supply. But that came to an abrupt halt late this summer when it came time for her ...

The U. Food and Drug Administration has approved Amgen and AstraZeneca's drug for a type of chronic inflammatory sinus ...

Six years since the FDA blessed Sanofi and Regeneron’s Dupixent as the first biologic to treat chronic rhinosinusitis with nasal polyps (CRSwNP), a second biologic therapy has broken through with a | ...

The FDA accepted a new drug application for a single inhaler that contains beclomethasone dipropionate, formoterol fumarate ...

The FDA has accepted for review the NDA for Chiesi’s single inhaler triple therapy for the maintenance treatment of asthma in adults.